Ada­gio press­es for­ward with their FDA pitch for Covid an­ti­body — de­spite Omi­cron flaws

Ada­gio, the Till­man Gern­gross biotech whose $750 mil­lion plan to build a pan-coro­n­avirus an­ti­body seem­ing­ly fell apart in the face of Omi­cron, is back again plead­ing its case.

The com­pa­ny re­leased da­ta from its piv­otal tri­als Wednes­day, an­nounc­ing that its an­ti­body ad­in­tre­vimab re­duced the risk of hos­pi­tal­iza­tion or death in par­tic­i­pants with mild to mod­er­ate Covid-19 by 66%, in­clud­ing a 77% re­duc­tion in pa­tients who were treat­ed with­in 3 days of symp­tom on­set.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER